Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enasidenib Maintenance Post-HSCT for IDH2-mutant Myeloid Neoplasms
NCT03515512Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enasidenib in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) and myelodysplastic syndrome (MDS), sponsored by Massachusetts General Hospital. Primary endpoints: Maximum Tolerated Dose at 28 days and Dose Limiting Toxicities at 28 days. Started Jul 2018; status: completed.
02
Drugs
enasidenib
03
Conditions
acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03515512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03515512.